ライフサイエンスコーパス: protooncogene

1 n hematopoietic stem cells and is a leukemia protooncogene.

2 eceptor tyrosine kinase encoded by the c-Met protooncogene.

3 like 2 (GRHL2) transcription factor as novel protooncogene.

4 of alpha-enolase in regulation of the c-myc protooncogene.

5 AMP might also include regulators of the Ras protooncogene.

6 lin-1 cellular gene is suppressed by the p53 protooncogene.

7 ed signaling appears to converge on the AP-1 protooncogene.

8 oligonucleotides targeted to the human c-myc protooncogene.

9 , and induction of the Stat5-regulated pim-1 protooncogene.

10 otein to activate transcription of the c-fos protooncogene.

11 early responsive genes, including the c-fos protooncogene.

12 ted domain (GRD) with the product of the ras protooncogene.

13 mutant tumors showed accumulation of the DEK protooncogene.

14 led homology to different regions of the FES protooncogene.

15 pathway of growth suppression and the bcl-2 protooncogene.

16 rtially inhibited by expression of the Bcl-2 protooncogene.

17 , including activating mutations in the KRAS protooncogene.

18 ned codon 61 (underlined) of the human N-ras protooncogene.

19 licate Nrf2 as both a tumor suppressor and a protooncogene.

20 to Elk-1 splice variant DeltaElk-1 and c-Fos protooncogene.

21 utagens that activate expression of cellular protooncogenes.

22 mors in C3H/He mice show upregulation of Int protooncogenes.

23 esis-i.e., extracellular matrix proteins and protooncogenes.

24 by an ordered program of turning off several protooncogenes.

25 hypothesis, cancer is caused by mutation of protooncogenes.

26 downregulating the activity of activated Ras protooncogenes.

27 Expression of the protooncogene A-myb is restricted to the developing CNS,

28 Mutations of the RET protooncogene (a growth factor receptor) occur in nearly

29 onin, neuron-specific enolase, and the c-met protooncogene (a hepatic growth factor/scatter factor re

30 Wnt-1 was first identified as a protooncogene activated by viral insertion in mouse mamm

31 cABL is a protooncogene, activated in a subset of human leukemias,

32 reast cancer cells and is a direct target of protooncogene ACTR/AIB1/SRC-3.

33 The protooncogenes Akt and c-myc each positively regulate ce

34 We identified the protooncogene and guanine nucleotide exchange factor Vav

35 atory elements that govern expression of the protooncogene and provide a new system for studying the

36 ectodomain of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/

37 ed to establish a relationship between c-ret protooncogene and some of the growth factors which are k

38 ar growth control genes, including the c-myc protooncogene and the gene encoding FAP-1 phosphatase.

39 asia type 2 (MEN2) have mutations in the RET protooncogene and virtually all of them will develop med

40 icularly interesting is the possible role of protooncogenes and angiogenic factors in the development

41 Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FG

42 probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene functio

43 the presence of dysplasia, and mutations in protooncogenes and tumor formation.

44 cond position of codon 61 of the human N-ras protooncogene, and was named the ras61 S-N1-BDO-(61,2) a

45 Because protooncogenes are conserved in evolution and are presum

46 rant expression in tumor cells, in which ras protooncogenes are frequently mutated.

47 , 61 (underlined), and 62 of the human N-ras protooncogene, are described.

48 Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO

49 tified Cbl, the protein product of the c-cbl protooncogene, as an early tyrosine kinase substrate upo

50 BV integrations to function as activators of protooncogenes, as well as agents of the loss of tumor s

51 he SRSR(61,2) adduct, derived from the N-ras protooncogene at and adjacent to the nucleotides encodin

52 virus (HCV) core protein regulates cellular protooncogenes at the transcriptional level; this observ

53 The protooncogene Bcl-2 functions as a suppressor of apoptos

54 The protooncogene bcl-2 is known to be a potent regulator of

55 Expression of the human protooncogene bcl-2 protects neural cells from death ind

56 The protooncogene BCL-6 is also involved in TH2 differentiat

57 Bcr-Abl, the product of the protooncogene bcr-abl, is a constitutively active protei

58 oplasia related to insertional activation of protooncogenes by retroviral vectors have raised serious

59 The protooncogene c-abl encodes a nonreceptor tyrosine kinas

60 Cbl is the product of the protooncogene c-cbl and is involved in T cell antigen re

61 The protooncogene c-Cbl has recently emerged as an E3 ubiqui

62 TCF alone does not bind the SRE of the protooncogene c-fos, but requires the prior assembly of

63 actors activating transcription factor 3 and protooncogene c-fosDLCs could represent a promising adju

64 The protooncogene c-jun encodes the founding member of the a

65 Although the protooncogene c-Jun plays a critical role in cell prolif

66 ultures induces the receptor tyrosine kinase protooncogene c-kit and that high levels of c-Kit expres

67 he major recent finding of a mutation in the protooncogene c-kit which is unique to gastrointestinal

68 ng up on our previous novel finding that the protooncogene c-Maf of the basic leucine zipper family o

69 The protooncogene c-met encodes the tyrosine kinase receptor

70 Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumo

71 Previous reports have suggested that the protooncogene c-myb participates in T cell development i

72 ) phase, whereas coexpression of p53 and the protooncogene c-myc induces apoptosis.

73 Here we show that the protooncogene c-Myc is an essential early regulator of n

74 nse oligodeoxynucleotides suggested that the protooncogene c-myc is obligatory for activation-induced

75 The protooncogene c-myc regulates cell growth, differentiati

76 gion, including translocations involving the protooncogene c-MYC, have been frequently reported in pe

77 ociated protein, to the kinase domain of the protooncogene c-ROS.

78 ropoietin regulates the transcription of the protooncogenes c-myc and c-myb by discrete protein kinas

79 receptor, myeloproliferative leukemia virus protooncogene (c-Mpl, or Mpl), controls HSC homeostasis

80 thway, to increase the expression of certain protooncogenes (c-fos, c-myc and c-jun) and growth facto

81 expression of immediate-early genes (IEGs), protooncogene, c-Fos, and zinc finger protein, Zif268, a

82 TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun.

83 The mRNA levels of two growth-related protooncogenes, c-fos and c-myc, were up-regulated signi

84 To explore whether the protooncogenes, c-fos/c-jun, might be involved in regula

85 Deregulated expression of two other protooncogenes, c-myc and c-myb, also has been shown to

86 that transcriptional activation of the TCL1 protooncogene can cause malignant transformation of T ly

87 But there is no evidence that known mutated protooncogenes can transform human cells.

88 ein in oncogenesis and establishes SKP2 as a protooncogene causally involved in the pathogenesis of l

89 complex is the 120-kDa product of the c-cbl protooncogene (Cbl).

90 integration sites near or within established protooncogenes (Chd9, Slamf6, Tde1, Camk2b, and Ly6e), d

91 s orthologous to human 11q22, which contains protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1.

92 The HMGA1 protooncogene codes for two closely related isoform prot

93 uced c-src/tubulin association indicates the protooncogene complexes primarily, if not exclusively, w

94 Significantly, several protooncogenes contain DEF domains and are regulated by

95 dexamethasone treatment suggests that these protooncogenes could mediate the effect of glucocorticoi

96 esent in the 3' untranslated regions of many protooncogene, cytokine, and lymphokine messages target

97 st, an inducible activated form of the Raf-1 protooncogene (delta RAF-1:ER) was expressed in these ce

98 its PSC cell proliferation by repressing the protooncogene dmyc.

99 ell cycle regulation through binding the Akt protooncogene; dysfunction in either may account for the

100 amino acid substitutions vis-a-vis the c-src protooncogene-encoded product pp60c-src.

101 The human ECT2 protooncogene encodes a guanine nucleotide exchange fact

102 The c-myb protooncogene encodes a highly conserved 75-89-kDa trans

103 The c-rel protooncogene encodes a member of the Rel/nuclear factor

104 The c-fes protooncogene encodes a nonreceptor tyrosine kinase (Fes

105 The c-fes protooncogene encodes a nonreceptor tyrosine kinase (Fes

106 The Gfi-1 protooncogene encodes a nuclear zinc-finger protein that

107 The c-kit protooncogene encodes a receptor tyrosine kinase that is

108 e epithelial cell transforming gene 2 (ECT2) protooncogene encodes a Rho exchange factor, and regulat

109 The Akt protooncogene encodes a serine-threonine protein kinase

110 The c-ski protooncogene encodes a transcription factor that binds

111 The c-KIT protooncogene encodes KIT, a tyrosine kinase that is the

112 l translocations commonly activate the BCL-2 protooncogene, endowing B cells with a selective surviva

113 uences in the 5' untranslated regions of the protooncogenes erbB-2 and erbB-3.

114 17beta-Estradiol (E2) induces c-fos protooncogene expression in MCF-7 human breast cancer ce

115 processes as diverse as cell cycle control, protooncogene expression, cellular defense against HIV i

116 a gene-specific means of inhibiting specific protooncogene expression.

117 onsequence of combined HOXB4 and deregulated protooncogene expression.

118 otein shares extensive homology with the maf protooncogene family.

119 The cbl-b gene is a member of the cbl protooncogene family.

120 gets multiple transcriptional activators and protooncogenes for ubiquitin-mediated degradation.

121 anslation initiation factor eIF4E is a novel protooncogene found over expressed in most breast carcin

122 The Ki-ras protooncogene frequently is mutated in colorectal adenoc

123 The RAS protooncogene has a central role in regulation of cell p

124 Overexpression of the MYC protooncogene has been implicated in the genesis of dive

125 Overexpression of the HER2/Neu protooncogene has been linked to the progression of brea

126 Tyrosine phosphorylation of the Cbl protooncogene has been shown to occur after engagement o

127 Although sporadic gain-of-function of protooncogenes has been successfully modeled in mice, ge

128 Although initiating mutations in the ret protooncogene have been found in familial and sporadic m

129 t specific protein subdomains within the Vav protooncogene have in the development of these two disti

130 that are conditionally deleted for the c-jun protooncogene in epidermis are born at expected frequenc

131 enic mice that conditionally express the MYC protooncogene in hematopoietic cells.

132 the protumorigenic stabilization of the MDM4 protooncogene in human HCC by way of a posttranscription

133 alpha stimulates the expression of the FRA-1 protooncogene in human pulmonary epithelial cells using

134 Expression of the Wnt-1 protooncogene in mammary glands of transgenic mice expan

135 nding protein that is homologous to a T cell protooncogene in three well-conserved domains.

136 ptor tyrosine kinase, is unusual among human protooncogenes in that its mutant alleles are implicated

137 hough originally described for their role as protooncogenes in the development of several types of hu

138 oblastoma Ras viral oncogene homolog (N-Ras) protooncogenes in the liver by way of hydrodynamic gene

139 s identified a remarkable number of putative protooncogenes in these lymphomas, which included loci t

140 ctivated protein kinase pathways and several protooncogenes, including c-myc and Pim-1.

141 rowth regulator dMyc, a homolog of the c-myc protooncogene, induces cell competition and leads to the

142 formation of these cells by translocation of protooncogenes into the immunoglobulin (Ig) loci.

143 The protein product of the c-cbl protooncogene is a 120-kD protein that is expressed in e

144 The deregulation of the c-myc protooncogene is a critical oncogenic event in the devel

145 The c-myc protooncogene is a key regulator of cell proliferation w

146 The Vav protooncogene is a multidomain protein involved in the r

147 The product of the c-abl protooncogene is a nonreceptor tyrosine kinase found in

148 The c-maf protooncogene is a T helper cell type 2 (Th2)-specific t

149 The MYC protooncogene is a transcription factor whose overexpres

150 h factor/scatter factor encoded by the c-met protooncogene is also expressed in limb muscle progenito

151 Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, wh

152 The MYC protooncogene is associated with the pathogenesis of mos

153 The Vav protooncogene is expressed almost exclusively in hematop

154 The MYC protooncogene is frequently deregulated in human cancers

155 t has been hypothesized that gain of the MYC protooncogene is of central importance in trisomy 8, but

156 The product of Cbl protooncogene is one such regulator, which functions as

157 The c-myc protooncogene is overexpressed in a variety of human can

158 The TCL1 protooncogene is overexpressed in many mature B cell lym

159 The neu/erbB2 protooncogene is overexpressed in numerous human cancers

160 Here we show that induction of the MYC protooncogene is required for cell transformation by vIR

161 The c-Myb protooncogene is required for definitive hematopoiesis i

162 r transcriptional up-regulation of the c-fos protooncogene, is constitutively occupied by a protein c

163 ctor receptor (M-CSFR), encoded by the c-fms protooncogene, is overexpressed on microglia surrounding

164 e significant cytoplasmic levels of Bcl-2, a protooncogene known to prolong cellular viability and to

165 anscriptional activation) why known, mutated protooncogenes lack transforming function in human cells

166 Intracellular activated Notch (ICN) is a protooncogene linked to the transcription activation of

167 ranslocations involving antigen receptor and protooncogene loci, it is critical to understand the typ

168 Which protooncogene may have the dominant role in embryonic re

169 e identified the essential p53 inhibitor and protooncogene MDM2 as a putative target.

170 The implications of a protooncogene-mediated suppression of TSP expression are

171 n human breast cancer, overexpression of the protooncogene MET is strongly associated with poor progn

172 tiated tumorigenesis with a transgene of the protooncogene MET or by hydrodynamic transfection of MET

173 iquitously expressed protein, related to the protooncogene Myb, that is present at telomeres througho

174 The protooncogene MYC encodes the c-Myc transcription factor

175 The protooncogene MYC has been implicated in both the prolif

176 The protooncogene MYC plays an important role in the regulat

177 We show that the protooncogene Myc regulates the expression of p48 throug

178 ary rodent fibroblasts when coexpressed with protooncogene myc.

179 ssed to mammary adenocarcinoma when a second protooncogene, MYC, was overexpressed, indicating that M

180 inhibition elicited by overexpression of the protooncogene MYCN.

181 Induction of a protooncogene, normally involved in mitogenic responses,

182 The human protooncogene Nup214 was first identified as a target fo

183 Activation of the c-abl protooncogene occurs during the generation of both the A

184 K/SAPK leads to the phosphorylation of c-JUN protooncogene on serines 63 and 73.

185 can cause tumors when they integrate near a protooncogene or tumor suppressor gene of the host.

186 The KIT protooncogene or, less frequently, platelet-derived grow

187 d tumors result in deregulated expression of protooncogenes or creation of chimeric proteins with tum

188 cancers involve either somatic activation of protooncogenes or inactivation of tumor-suppressor genes

189 The targeted repair of mutant protooncogenes or the inactivation of their gene product

190 ted by microinjecting MB targeted to the vav protooncogene, or control MB, into K562 human leukemia c

191 e proteins as certain cellular genes, termed protooncogenes, our data must also be relevant to the on

192 was required for upregulation of the T cell protooncogene p21.

193 link between the interleukin-2 receptor, the protooncogene PKB, and p70 S6 kinase.

194 Members of the myc family of nuclear protooncogenes play roles in cell proliferation, differe

195 The c-myc protooncogene plays a key role in the abnormal growth re

196 The c-myc protooncogene plays an important role in the abnormal gr

197 c-myb, a protooncogene prevalently expressed in the hematopoietic

198 The c-cbl protooncogene product (p120(cbl)) is a known substrate o

199 cells have been identified as the p120 c-Cbl protooncogene product and the p85 subunit of phosphatidy

200 The protooncogene product Cbl has emerged as a negative regu

201 The protooncogene product Cbl has emerged as a novel signal

202 The Cbl protooncogene product has emerged as a negative regulato

203 The Cbl protooncogene product has emerged as a novel negative re

204 nt of NB-4 human cells with IFN-gamma, c-cbl protooncogene product is rapidly phosphorylated on tyros

205 resent in activated T cell lysates as Cbl, a protooncogene product of unknown function which was foun

206 The Ser/Thr kinase Raf-1 is a protooncogene product that is a central component in man

207 arrow macrophages (BMMs) to express c-src, a protooncogene product that we demonstrate is a specific

208 ntracellular substrates, including the 95-kD protooncogene product Vav.

209 ces rapid tyrosine phosphorylation of Cbl, a protooncogene product which has been implicated in intra

210 ation of cellular proteins, including Cbl, a protooncogene product whose function remains unclear.

211 phosphotyrosine-binding (PTB) domain of the protooncogene product, c-Cbl.

212 stinct signaling cascade involving the c-cbl protooncogene product, CrkL adapter, and small G protein

213 ic exposure elicited expression of the c-fos protooncogene product, FOS, in nucleus of the solitary t

214 ely high levels of autoantibodies to the DEK protooncogene product.

215 their interaction with several oncogene and protooncogene products.

216 The bcl-2 protooncogene promotes cell survival and protects agains

217 unodominant peptide, E75, from the HER-2/neu protooncogene protein recognized by CTL.

218 re the association of Smad3 with the nuclear protooncogene protein Ski in response to the activation

219 re the association of Smad3 with the nuclear protooncogene protein SnoN.

220 of most other 14-3-3 partners, including the protooncogene Raf, which nevertheless remain capable of

221 Mutations that activate the protooncogene ras, such as loss of Nf1, cooperate with i

222 Hepatocyte Growth Factor (HGF) and its protooncogene receptor c-Met regulate osteoclast functio

223 ified an interaction of GPX1 with the orphan protooncogene receptor tyrosine kinase ROS1.

224 novel putative targets identified, the c-fos protooncogene regulator ELK-1 was characterized as the f

225 Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain

226 , 61 (underlined), and 62 of the human N-ras protooncogene, results from trans opening of (1R,2S,3S,4

227 The receptor tyrosine kinase ret protooncogene (RET) is implicated in the pathogenesis of

228 To demonstrate this, we targeted the c-MYB protooncogene's mRNA in human leukemia cells with fully

229 e, microsatellite instability, and the B-Raf protooncogene, serine/threonine kinase (BRAF), mutation)

230 els of mRNA and protein encoded by the c-myc protooncogene set the balance between proliferation and

231 The data suggest that, although a number of protooncogenes share similar catalytic domains, c-ret pl

232 Protooncogene Ski was identified based on its ability to

233 ates microtubules in a manner similar to the protooncogene, specifically coimmunoprecipitates with c-

234 le strains through insertional activation of protooncogenes, such as members of the wnt and fibroblas

235 ancer hypothesis holds that mutated cellular protooncogenes, such as point-mutated proto-ras, "play a

236 The regions encode a family of protooncogenes (TCL1, MTCP1, and TCL1b) of unknown funct

237 gene, and the receptor tyrosin kinase (RET) protooncogene that are associated with cystic fibrosis,

238 Our results identify UbcH10 as a prominent protooncogene that causes whole chromosome instability a

239 Evi1 is a myeloid-specific protooncogene that encodes 145 kDa and 88 kDa proteins v

240 ctor receptor (EGFR) is a well-characterized protooncogene that has been shown to promote tumor progr

241 Protein kinase Tpl2/Cot is encoded by a protooncogene that is cis-activated by retroviral insert

242 odes a Trithorax-related chromatin-modifying protooncogene that positively regulates Hox genes.

243 rough overexpression or mutation, is a major protooncogene that provides an attractive molecular targ

244 ificant decrease of mRNA level for the c-myc protooncogene that regulates telomerase.

245 also mediates the ubiquitination of another protooncogene, the non-receptor tyrosine kinase c-Src, a

246 s with unconstrained activation of the c-Met protooncogene to induce hepatocarcinogenesis via in vitr

247 threonine protein kinase encoded by the Tpl2 protooncogene transduces Toll-like and death receptor si

248 The protein product of this protooncogene, TrkA, is a receptor tyrosine kinase for n

249 hosphorylation of a substrate peptide by the protooncogene tyrosine kinase c-src.

250 gineered to overexpress the HER-2/neu/erbB-2 protooncogene under the control of a mammary-specific pr

251 )C(22)), bearing codon 12 of the human N-ras protooncogene (underlined), was determined.

252 C), encompassing codon 12 of the human n-ras protooncogene (underlined), were refined from 1H NMR dat

253 We show herein that the product of the protooncogene vav is constitutively Tyr-phosphorylated i

254 ll receptor ligation by interacting with the protooncogene Vav, which leads to subsequent tyrosine ph

255 several intracellular proteins including the protooncogene Vav1.

256 a single cDNA encoding a variant of the TrkA protooncogene was isolated.

257 , 61 (underlined), and 62 of the human N-ras protooncogene, was determined by NMR.

258 ns 60, 61(italic), and 62 of the human N-ras protooncogene, was determined.

259 , 61 (underlined), and 62 of the human N-ras protooncogene, was determined.

260 Mutations in codons 12 and 13 of the Ki-ras protooncogene were analyzed in baseline adenomas 0.5 cm

261 In addition, the mutated protooncogenes were amplified in HCV-associated lymphoma

262 piens, HSA) DNA probes for GLI, HST and INT2 protooncogenes were used to identify their homologous lo

263 , 61 (underlined), and 62 of the human n-ras protooncogene, were examined by 1H NMR.

264 , 61 (underlined), and 62 of the human N-ras protooncogene, were refined from (1)H NMR data.

265 c-myc is an important protooncogene whose misregulation is believed to causall

266 romosomal translocations juxtaposing the MYC protooncogene with regulatory sequences of immunoglobuli

267 The role of various receptor-like protooncogenes, with the emphasis on c-ros and c-ret, wa

268 Receptor-like protooncogenes, with tyrosine kinase catalytic domains,

269 ome this defect by ectopic expression of the protooncogene Wnt-1.